AI assistant
Sending…
EyePoint Pharmaceuticals, Inc. — Director's Dealing 2024
Sep 5, 2024
32254_dirs_2024-09-05_43f8e026-6ffa-494b-84cb-120565938bcb.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2024-09-03
Reporting Person: Hassan Fred (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-09-03 | Stock Options (Right to buy) | $8.16 | A | 60000.00 | Acquired | 2034-09-03 | Common Stock (60000.00) | Direct |
Footnotes
F1: The option becomes exercisable in three ratable annual installments beginning on September 3, 2025.
More from EyePoint Pharmaceuticals, Inc.
Regulatory Filings
2026
May 14
Regulatory Filings
2026
May 6
Investor Presentation
2026
Apr 13
Director's Dealing
2026
Mar 24
Legal Proceedings Report
2026
Mar 20
Regulatory Filings
2026
Mar 4
Regulatory Filings
2026
Mar 2
Director's Dealing
2026
Feb 18
Major Shareholding Notification
2026
Feb 12
Director's Dealing
2026
Jan 7